Category Archives: Human Longevity

March 19, 2021 @ 13:28 by Chloe Holmes

Together with VOICE, The UKs National Innovation Centre for Ageing will launch their very first citizen-led community in the US.

Through a commercial agreement, VOICE (Valuing Our Intellectual Capital & Experience) and the UKs National Innovation Centre for Ageing (NICA) have set up a partnership with a non-profit organisation called amazing.community.

Headquartered in New Jersey (US) the amazing.community supports women aged 45+ as they navigate the present and future of work in this digital world; the organisation offers cutting edge skills building opportunities, curated resources, and an open virtual door for women 45+ to connect meaningfully with each other.

This new partnership will help build a more diverse VOICE community and facilitate cultural exchanges between US and UK. NICA and amazing.community will work together to explore the impact of technology at work, ageism, gender equality, cultural differences and the many issues and challenges that need to be addressed to ensure women over 45 thrive in the workplace now and in the future.

All this is building a deep global knowledge and rich consumer insights on healthy ageing. It gives businesses, entrepreneurs, innovators, and policy makers a novel and unique source of data and insights, building the evidence base to rapidly inform the development of new products and services helping people to live well for longer and tapping into a billion-pound longevity economy.

NICA, who are based within Newcastle University, UK on Newcastle Helix, is the UK home of Ageing Intelligence, which brings together data driven insight and human experiences to help bring new products, business models and services to market. VOICE is part of NICA and leads dialogue with citizens on what is needed for healthy ageing.

VOICE currently has a citizen network of more than 8,000 people the UK and this expansion is part of NICAs strategy to provide services and insight on ageing at a global level. It is intended that this business model will be replicated in other countries around the world, building a broader repository of data and insight to empower new business opportunities and ideas.

Professor Lynne Corner, chief operating officer at NICA and director of VOICE said: This marks the first step in our global ambitions for the VOICE community and we are thrilled to partner with the wonderful team at amazing.community and support ageing innovation in the US.

This is a strategic decision to develop a more culturally and gender diverse community to generate broader, deeper, richer insights and cultural exchanges between individuals from all over the world. It will provide to clients, business and policy makers a novel and unique source of insight.

This new business model is not only commercially viable, but also a way to empower parallel communities to come together and amplify their voices sharing experiences, exchanging insights, and building on common ground. Our plans will not only support international longevity economies but make a lasting impact on peoples lives helping them live well for longer.

amazing.community will be able to take advantage of ten years of operational expertise in community engagement from the VOICE network in the UK. Branded as Amplified by VOICE, amazing.community has customized the VOICE digital platform to engage and grow their existing community as well as to invite more robust collaboration with companies, non-profits and other organisations.

Dr. Ashley Ater Kranov, executive director of amazing.community, said: Im thrilled to announce our global partnership with VOICE. It has been nearly a year in the making and we are beyond ready to bring our communities together.

This partnership forwards one of our strategic initiatives: to establish close ties with a center for aging known for applied research, community engagement, and a commitment to transforming individual lives and impacting policy. Our collaboration will allow each of our communities to participate in tech skills building opportunities, quality of life research studies and special interest group discussions offered by both organizations.We believe doubling our offerings and opening the door to an international community will meaningfully enhance our efforts to expand the work horizon for women 45+ who are looking to re-enter the workforce, pivot to a new career or start their own businesses.

To celebrate this global partnership, and to bring both communities together for an engaging cross Atlantic conversation, they will watch the exclusive premiere of the film Les Dames (Ladies).

The acclaimed Swiss film Ladies by directors Stphanie Chuat, Vronique Reymond is a movie that reveals the passions, intimacy, and desires of five women who, at the dawn of their 60s or older, dream of their future. This will be a first-world premiere and will also mark the start of a joint research piece on love, life, companionship for women in later life.

For more information or to sign up to be part of the VOICE community visit https://www.voice-global.org/about/ (UK) or https://amazing.community (US).

Here is the original post:
Global expansion for UK National Innovation Centre with a new VOICE in the US - North East Times

EDISON BIO is expanding human health potential.

HOUSTON (PRWEB) March 19, 2021

Houston health tech company EDISON BIO has launched what may be the most comprehensive executive health exam on the planet. This new physical of the future aggregates a wide array of health data to create a truly universal digitalization of patients minds and bodies focused on improving longevity and performance. EDISON BIOs Artificial Intelligence, combined with a team of medical experts, analyzes health changes at the first signs of detection long before they have the chance to progress into serious health concerns. By analyzing this personalized data, EDISON BIO can uncover potential health risks and create an educational, highly personalized health strategy focused on optimizing diet, exercise, and lifestyle to improve overall performance and longevity. This approach aims to empower people to achieve the most in-depth understanding of all areas of their health in a way never before imagined.

Despite all the advances of modern medicine, todays healthcare system still largely takes a reactionary approach, catching disease only after symptoms manifest. By that time, it is often too late to reverse the resulting damage. The team at EDISON BIO believes that no one should have to wait until their disease becomes too harmful for treatment and is accelerating access to the latest in medical detection technology.

In contrast to the routine exam and minimal blood work done by many doctors today, EDISON BIO uses the latest technology to collect extensive data including full-body MRI imaging, a full array of genomic technology including whole genome sequencing, extensive blood analysis, and diet, lifestyle, and mental health evaluations to determine current and future health risks. This scientifically quantified data empowers members with confidence and peace of mind as to the comprehensive state of their health.

EDISON BIOs founder realized the need for proactive awareness of health risks when a cancer screening technology saved his mothers life. Around the same time, a family friend passed away after cancer was detected too late. He and his team have spent nearly twenty years researching and experimenting with medical technology to make medicine more personalized and less reactionary in nature. He believes that it will change the way people engage with their health through anticipating concerns early on and empowering people with personalized tools to achieve their optimum health.

EDISON BIO conducts exams at their members preferred location, including their homes, corporate offices, or wherever they are requested. After the biomarkers are analyzed, they offer an easy-to-understand educational plan to address concerns as well as rapid access to the worlds leading experts if a rare condition or disease is detected.

EDISON BIO is using evidence-based, data-driven technology to expand human health potential. Named in homage to Thomas Edisons invention of the light bulb, EDISON BIO is illuminating the future of healthcare in the twenty-first century by providing a more personalized, preventive, and data-driven approach to health.

EDISON BIO Contact: http://www.edisonbio.com / support@edisonbio.com / Phone: 888-366-0123

Share article on social media or email:

See original here:
EDISON BIO Launches Advanced Executive Health Exam For Early Detection Of Health Risks - PR Web

Light and heat sensors on a building at the University of Southern Denmark adjust shutters to optimize indoor conditions.

The Smart City Index (1) defines a smart city as an urban setting that applies technology to enhance the benefits and diminish the shortcomings of urbanization for its citizens. The top-ranked city, Singapore, has addressed urban challenges with information technology since 2014 through its Smart Nation Initiative (2). The influence of technology is reflected in the city's open platform for sharing energy data, crowd-sourced location data for smart navigation, and even online forums for citizen participation in policy-making (2). The smart city concept requires the acquisition of massive amounts of data in real time, and large networks of smart devices must spread the burden of communication and processing evenly across the network to prevent information overload at its center. Opportunities to solve this challenge have recently emerged through the development of increasingly smart materials that can sense, process, and respond to environmental stimuli without centralized resources.

A recent market analysis predicted that the number of connected devices, sensors, and actuators that constitute the Internet of Things (IoT) will reach more than 46 billion in 2021, driven largely by reduction in hardware costs to as little as $1 per device (3). Inexpensive connected sensing devices measuring strain, temperature, and humidity (4), as well as the enhancement of indirect sensing methods that use computer vision and crowd-sourcing (5), provide vast amounts of data to quantify the built environment (6). The ability to continuously monitor the physical state of infrastructure with high resolution in time and space has exciting implications for sustainability and equity. Quantitative, data-driven decision-making can enable predictive maintenance in place of conventional intuition-based workflow, although such automated systems can also learn to replicate human biases (7).

However, efficient decision-making based on these data streams becomes limited by the burden of transmitting and processing the raw, unprioritized data. As the number of connected devices rises, smart cities have shifted from a hierarchical network architecture based on cloud computing to a more decentralized information ecosystem. In this so-called fog computing model, data processing is performed at the edge of the network to avoid costly communication with a central cloud server (8). Alternatively, mist computing represents an even more extreme paradigm in which data processing is handled by microprocessors attached directly to the sensors and actuators. One advantage of mist computing is a reduced burden on communications systems by constraining information to a need-to-know basis. This approach has an added sustainability benefit because communication among IoT devices accounts for as much as five times the power consumption necessary for the computation itself (9).

Infrastructure decision-making can benefit from distributed sensor data if data can be processed efficiently. Data management can benefit from need-to-know processing strategies, as illustrated for the construction of a subway system, where tunneling can create ground-surface subsidence that can undermine an overlying building. At the city scale, analysis of these data can lead to decisions to mitigate subsidence impact, such as stopping tunneling or adding underlying support.

Orthogonal to these advances in IoT technology, multifunctional and responsive materials have been designed to substantially alter their shape or properties in response to external stimuli. When taken to the extreme, this concept results in living materials, which use biological organisms (10) as highly efficient chemical machines for sensing and responding to their environment. Such materials are engineered to sense and regulate their state at the microscopic scale to effect macroscopic structural or functional changes. A common function of smart or living materials is self-healing to improve the service life of a larger structure in support of its sustainability. For example, bacteria-triggered self-healing represents one of the most popularized concepts in living cementitious materials. Extensive research has been conducted on the use of extremophiles and engineered bacteria to imbue materials with the self-sensing capacity needed to trigger these self-healing properties (10).

In effect, these smart and living materials participate in an extreme version of the mist-computing model for structural health monitoring. Chemical gradients in the cement are detected, interpreted, and acted upon by means of incredibly low-power sensing and response mechanisms without increasing the communication and processing burden on the built environment. This latter point is critical because the electronic sensing and transmission of millimeter-scale chemical gradients across an entire smart city would absolutely overwhelm digital data processing systems. Information at this small scale is also irrelevant to decisions being made for an entire city block, so restricting it to an appropriate level reduces the cognitive load on stakeholders such as building managers and government policymakers (see the figure). This approach is analogous to how the human nervous system coordinates the contraction of many millions of cells through a hierarchy of control structures, rather than by consciously addressing individual muscle fibers.

Smart materials can also process data without the assistance of active biological matter. A fascinating example of computation in material substrates is the recent demonstration of photonic metamaterials (internally structured materials) that can solve complex mathematical equations (11). These devices exploit diffractive optics to leverage material microstructure into passive, all-optical transformations. A complementary idea is that of mechanologic, in which a mechanical metamaterial deforms in a preprogrammed way to combine computation and actuation (12). Given the rapid advancements in design and fabrication of these extraordinary materials, a next generation of smart materials may emerge with programmed thermal, optical, and mechanical responses acting as a self-sensing, self-actuating smart faade, or as a solar tracker to improve the efficiency of photovoltaic energy harvesting (13).

With connected sensors being deployed to provide real-time structural health monitoring of critical infrastructure [e.g., bridges, dams, residential and commercial buildings, and even temporary structures (14)], managing the flood of data is more important than ever to prevent smart cities from suffering analysis paralysis. Smart and living materials may push data processing to previously unimagined extremes, with the literal foundations of the built environment acting as analog-computing substrates. This approach should offer pronounced advantages for sustainability, including increased longevity of infrastructure, reduced waste from the proliferation of electronic sensors, and reduced power consumption from communications. Moreover, the current challenge to implementation of mist-computing infrastructures is tied to their complexity and size, which are too great to manage by centralized systems (15). Thus, autonomous smart materials present a compelling tool in achieving robust and sustainable structural health monitoring in smart cities of the future.

Acknowledgments: We thank Z. Ounaies for inspiring our research collaborations.

See the original post here:
Smart cities built with smart materials - Science

New York, March 16, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Stem Cell Therapy Industry" - https://www.reportlinker.com/p06033005/?utm_source=GNW In addition to being a global intelligence exchange platform, MarketGlass is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack. - Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

Abstract: - Global Stem Cell Therapy Market to Reach $242.3 Million by 2027 - Amid the COVID-19 crisis, the global market for Stem Cell Therapy estimated at US$127.5 Million in the year 2020, is projected to reach a revised size of US$242.3 Million by 2027, growing at aCAGR of 9.6% over the period 2020-2027. Allogeneic, one of the segments analyzed in the report, is projected to record 9.9% CAGR and reach US$228.6 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Autologous segment is readjusted to a revised 5.6% CAGR for the next 7-year period. - The U.S. Market is Estimated at $37.8 Million, While China is Forecast to Grow at 9% CAGR - The Stem Cell Therapy market in the U.S. is estimated at US$37.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$41.9 Million by the year 2027 trailing a CAGR of 9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.8% and 7.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.

Select Competitors (Total 33 Featured) -

Read the full report: https://www.reportlinker.com/p06033005/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Impact of Covid-19 and a Looming Global Recession Global Competitor Market Shares Stem Cell Therapy Competitor Market Share Scenario Worldwide: ( in %): 2020E Global Competitor Market Shares by Segment

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Allogeneic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Allogeneic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Autologous by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Autologous by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Gastrointestinal Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Gastrointestinal Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Musculoskeletal Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Musculoskeletal Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Wounds & Injuries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Wounds & Injuries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Adipose Tissue-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Adipose Tissue-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 29: World Historic Review for Bone Marrow-Derived MSCs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Bone Marrow-Derived MSCs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Cord Blood / Embryonic Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Cord Blood / Embryonic Stem Cells by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Cord Blood / Embryonic Stem Cells by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 35: World Historic Review for Other Cell Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Other Cell Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES Market Facts & Figures Market Analytics Table 37: USA Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 38: USA Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 39: USA 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 40: USA Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 41: USA Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 42: USA 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 43: USA Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 44: USA Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 45: USA 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

CANADA Table 46: Canada Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 47: Canada Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 48: Canada 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 49: Canada Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 50: Canada Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 51: Canada 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 52: Canada Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 53: Canada Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 54: Canada 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

JAPAN Table 55: Japan Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 56: Japan Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 57: Japan 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 58: Japan Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 59: Japan Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 60: Japan 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 61: Japan Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 62: Japan Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 63: Japan 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

CHINA Table 64: China Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 65: China Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 66: China 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 67: China Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 68: China Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 69: China 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 70: China Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 71: China Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 72: China 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

EUROPE Market Facts & Figures Market Analytics Table 73: Europe Current & Future Analysis for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Stem Cell Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 76: Europe Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 77: Europe Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 78: Europe 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 79: Europe Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 80: Europe Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 81: Europe 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

Table 82: Europe Current & Future Analysis for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 83: Europe Historic Review for Stem Cell Therapy by Cell Source - Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 84: Europe 15-Year Perspective for Stem Cell Therapy by Cell Source - Percentage Breakdown of Value Sales for Adipose Tissue-Derived MSCs, Bone Marrow-Derived MSCs, Cord Blood / Embryonic Stem Cells and Other Cell Sources for the Years 2012, 2020 & 2027

FRANCE Table 85: France Current & Future Analysis for Stem Cell Therapy by Type - Allogeneic and Autologous - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 86: France Historic Review for Stem Cell Therapy by Type - Allogeneic and Autologous Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 87: France 15-Year Perspective for Stem Cell Therapy by Type - Percentage Breakdown of Value Sales for Allogeneic and Autologous for the Years 2012, 2020 & 2027

Table 88: France Current & Future Analysis for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases - Independent Analysis of Annual Sales in US$ for the Years 2020 through 2027 and % CAGR

Table 89: France Historic Review for Stem Cell Therapy by Application - Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases Markets - Independent Analysis of Annual Sales in US$ for Years 2012 through 2019 and % CAGR

Table 90: France 15-Year Perspective for Stem Cell Therapy by Application - Percentage Breakdown of Value Sales for Gastrointestinal Diseases, Other Applications, Musculoskeletal Disorders, Wounds & Injuries and Cardiovascular Diseases for the Years 2012, 2020 & 2027

See the article here:
Global Stem Cell Therapy Market to Reach $242.3 Million by 2027 - GlobeNewswire

On arriving in London to seek his fortune, the rambunctious Scottish physician George Cheyne set about hobnobbing in coffee houses and taverns, where he ate lustily and swallowed down much liquor. Before long, he had ballooned to nearly 450 pounds. In a state of existential crisis and discerning that his mortality was in the balance, he published a self-help manual, An Essay of Health and Long Life (1724). In this bestselling treatise, he singled out tea, coffee, chocolate and snuff as being especially detrimental to the human condition.

This seminal work, among others, spawned a tradition of books addressing the topic of longevity which continues to this day. While Cheyne and others contrived innumerable methods designed to maintain good health and extend lifespans, the process of aging has itself invariably been viewed as an immutable part of human nature.

No longer, says Andrew Steele in his entertaining and thoughtful book Ageless (Doubleday, 352 pages, $29). While we wither and become frail after a mere seven or so decades, the humble Galpagos tortoise bumbles on healthily into a 175-year dotage. Capturing this traitknown as negligible senescenceis the holy grail of aging research.

So if, as Mr. Steele contends, tortoises get old without getting elderly, might we not master biological immortality and become ageless too? Were this achievable, the existence of a bristlecone pine tree in Californias White Mountains, estimated to be an extraordinary 4,850 years old, suggests that such potential extensions to our longevity might be more than mere tweaks. The fact that lifespans of different species vary so greatlysome mayflies emerge, mate and die within 5 minutes, while bowhead whales can live for more than 200 yearsindicates that our lifespan is programmed by evolution, rather than restricted by insurmountable constraints.

Ageless follows biologist George C. Williamss simple evolutionary explanation for why we age, based on a phenomenon called antagonistic pleiotropy. Put simply, genes selected to facilitate early successful reproduction may have detrimental effects as we get older. In Mr. Steeles words, it looks as if evolution has traded our future health for increased reproduction. Were we able to roll the clock back and redesign ourselves, we would doubtless find alternative genetic circuits that did not have these unfortunate consequences. Perhaps one day, Mr. Steele conjectures, we will be able to reprogram our genomes to remove this legacy. Fortunately, there may be more immediately accessible paths to a longer life.

Originally posted here:
Ageless Review: The Long Run - The Wall Street Journal

High-skilled foreign nationals, including doctors and engineers, rally on Capitol Hill in ... [+] Washington, D.C., to protest long delays in getting green cards on September 18, 2007, in Washington, D.C. The employment-based green card backlog has worsened since 2007. (Photo by Jahi Chikwendiu/The Washington Post via Getty Images)

Without a change in immigration law, it will be sometime in the year 2216195 years from nowwhen the last person born in India waiting today in the employment-based immigrant backlog is expected to receive a green card. Barring advances in human longevity, businesses and high-skilled foreign nationals must rely on Congress to solve this problem and enact reasonable policies to welcome highly skilled people who want to become Americans.

The Scope of the Problem: H-1B and L-1 (intracompany transferee) are temporary statuses, meaning if someone wishes to remain in the United States, they must obtain an employment-based immigrant visa (or green card) that grants permanent residence. However, there is far greater demand for high-skilled individuals than the limited number of employment-based green cards allotted by Congress.

Since 1990, when Congress set the annual limit on employment-based immigrants at 140,000 (and 65,000 H-1B temporary visas), changes in technology have accelerated the demand for high-skilled technical labor. Congress established the current employment-based limits before the internet became a part of daily life. It also predates the iPhone, the iPad, YouTube, e-commerce, Netflix, Google, cloud computing and thousands of innovative companies and technologies that have come into existence and fueled the demand for high-skilled labor.

U.S. businesses would still need more scientists and engineers to grow and innovate even if the number of Americans earning degrees in science and engineering had explodedand it hasnt.

Between 1995 and 2015, full-time U.S. graduate students in electrical engineering decreased by 17%. The number of full-time U.S. graduate students in computer science increased by 45% from 1995 to 2015, while international graduate students increased by over 480%. (H-1B visa fees paid by employers have funded approximately 100,000 college scholarships for U.S. students in science and engineering.)

As of March 2020, the backlog in EB-1, EB-2 and EB-3the employment-based first, second and third preferenceswas 915,497, according to the Congressional Research Service (CRS).

Without Congressional action, notes CRS, the problem will grow worse: The total backlog for all three categories would increase from an estimated 915,497 individuals currently to an estimated 2,195,795 individuals by FY 2030.

Let that number sink in: Within a decade, more than 2 million people will be waiting in line, most for many years or even decades, for employment-based green cards. And there are indications this underestimates the problem.

Table 1 shows that in FY 2018 only about 4,500 Indians obtained permanent residence in the employment-based second preference and fewer than 6,000 received green cards in the employment-based third preference. (The National Foundation for American Policy obtained the data via a Freedom of Information Act request.)

CRS estimates the annual demand for employment-based green cards in the three preference categories is 262,376 (including dependents). This is based on petitions U.S. Citizenship and Immigration Services (USCIS) approved in FY 2018. CRS explains the backlog grew because there is a current limit of 120,120 green cards for the three employment-based immigration categories.

Another problem is that Congress established a per-country limit of 7% for each country that burdens mainly potential employment-based immigrants from India but also affects people born in China and the Philippines. The law, in effect, gives the same number of green cards for employment to India as it does Iceland.

In the employment-based second preference (EB-2): Under current law, and owing to a limited number of green card issuances, the current backlog of 568,414 Indian nationals would require an estimated 195 years to disappear, according to CRS. David Bier of the Cato Institute predicts about 186,038 Indian immigrants will die . . . before they receive green cards even if they could remain in line forever.

By FY 2030, [the] estimated wait time would more than double, according to CRS. Under S. 386, the estimated wait time for newly approved EB-2 petition holders would shrink to 17 years, and in FY 2030, the wait time would be 37 years, the same as for all other foreign nationals.

S. 386 was a bill in the last Congress sponsored by Sen. Mike Lee (R-UT) that would have eliminated the per-country limit for employment-based immigrants. Rep. Zoe Lofgren (D-CA) wrote H.R. 1044 with Rep. Ken Buck (R-CO) and it passed the House in July 2019. The companion bill, S. 386, was blocked in the Senate for more than a year. It became a Christmas tree for extraneous immigration provisions. The Senate finally approved S. 386 near the end of the session but the House found the provisions to be objectionable and it did not become law. The bill would not have increased the number of employment-based green cards but would have reduced the wait times for those waiting the longest for permanent residence, particularly professionals from India.

Without any change in the law, CRS predicts: Currently, new Indian beneficiaries entering the EB-3 [employment-based third preference] backlog can expect to wait 27 years before receiving a green card. (The wait time would be much longer in the EB-2 category.)

Scientists and engineers waiting for their green cards may see their children who have lived in the United States for years be forced to leave the country when they age out of their place on a mother or fathers immigration application when reaching 21 years old. USCIS policies during the Trump administration caused many spouses of H-1B visa holders waiting for green cards to lose their work authorization due to long processing delays.

New Immigration Bill Would End the Employment-Based Backlog: The U.S. Citizenship Act, developed by the Biden administration, would eliminate the employment-based backlog within 10 years through various provisions, according to a National Foundation for American Policy (NFAP) analysis.

First, the bill would no longer count spouses and children toward the annual limit, which would approximately double the annual number of employment-based green cards. Second, the legislation increases the annual limit for family-sponsored immigrants and allows unused numbers from the family categories to be used by the employment categories. That means once the family backlog is eliminated, which NFAP predicts could happen within 5 or 6 years, backlog reduction in the employment-based categories would accelerate.

Third, the bill eliminates the per-country limit. Fourth, the legislation allows unused green cards from earlier years to be redirected to reduce family and employment backlogs.

The bill also contains a provision, which NFAP has recommended, to allow any individuals who wait at least 10 years with an approved immigrant petition to receive permanent residence without numerical limit. If Congress passed only this reform, it would help many people and bring certainty to otherwise interminable waits for many employment-based immigrants.

Related to the backlog, in its final days, the Trump administration published a final rule designed to price employment-based immigrants and H-1B visa holders out of the U.S. labor market. The regulation would boost required wages 23% to 41% depending on the occupation, according to an NFAP study. The regulation could block people waiting for green cards if the new required salary is too high for an employer to retain them in H-1B status. (Individuals can be extended in H-1B status while waiting for an employment-based green card.)

If the Biden administration keeps the rule, it would be a significant victory for former White House adviser Stephen Miller and opponents of immigration.

Numerous studies and private wage surveys show that there is no evidence high-skilled foreign nationals are paid less than comparable U.S. professionals. If employers were forced to pay high-skilled immigrants 41% more than comparable U.S. workers, one would expect critics would still claim the immigrants were paid less because that is typically the only argument put forward against high-skilled foreign nationals who work in America. Members of Congress are repeatedly told to believe the only value someone born in another country offers a U.S. business or the U.S. economy is a willingness to work for less money.

If we have learned one thing from the pandemic, it is how valuable immigrants are to America. Immigrants play key roles in the two companies responsible for the Covid-19 vaccines Americans are receiving to protect their lives. Modernas leaders, two cofounders and critical scientific personnel are immigrants, as are the chief executive (and chief science officer) of Pfizer and a key scientist (Katalin Karik) who made a crucial breakthrough on messenger RNA, as noted in a December 2020 article. Even the founders of Pfizer were immigrants.

We have blown the opportunity to maximize the incredible high-skilled immigrants in this country, said Sen. Kevin Cramer (R-ND) at a recent hearing. The backlog of green cards is immoral to me. Will this be the year moral outrage and economic sense lead to a solution for employment-based immigrants?

See the original post here:
Immigration Bill Shows Need To End Employment-Based Immigrant Backlog - Forbes

Anti-Senescence Therapy Market 2021: Latest Analysis

Los Angeles, United State,March 2021, The study published on the Anti-Senescence Therapy market is a systematic review that includes key parameters and indicators that are crucial to market understanding. The data from the years 2015 to 2020 is used to show the status and size of the market. The report also includes a total market value for the forecast period, along with the CAGR. The introductory chapter, along with the product description and market scope, provides an overview of the Anti-Senescence Therapy industry. The study also analyzes market dynamics in product-related matters along with developments in the growth of the industry.

Anti-Senescence Therapy Market 2021 Research report contains a qualified and in-depth examination of Anti-Senescence Therapy Industry. At first, the report provides the current business situation along with a valid assessment of the Anti-Senescence Therapy Market Analysis. This report is partitioned based on driving Anti-Senescence Therapy Market Top Key players, application and regions. The progressing Anti-Senescence Therapy economic situations are additionally discovered in the report.

Major Key Manufacturers ofAnti-Senescence Therapy Market are:Unity Biotechnology, OisinBiotechnologies, AgeX Therapeutics, Siwa Therapeutics, Cleara Biotech, Calico, Sierra Sciences, Human Longevity (HLI), Numeric Biotech, Recursion Pharmaceuticals, Proteostasis Therapeutics, Senolytic Therapeutics, Allergan

Request Free Sample Reportwith Complete TOC and Figures & Graphs@https://www.mraccuracyreports.com/report-sample/205864

Market Segment by Type covers:Gene Therapy, Immunotherapy, Others

Market Segment by Applications can be divided into:Unity Biotechnology, OisinBiotechnologies, AgeX Therapeutics, Siwa Therapeutics, Cleara Biotech, Calico, Sierra Sciences, Human Longevity (HLI), Numeric Biotech, Recursion Pharmaceuticals, Proteostasis Therapeutics, Senolytic Therapeutics, Allergan

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Anti-Senescence Therapy market.

Production, consumption, revenue, market share, and growth rate are the key targets forAnti-Senescence Therapy Market forecast from 2013 to 2026 (forecast) in these regions:

Benefits of buying the report:

Impact Of COVID-19

The most recent report includes extensive coverage of the significant impact of the COVID-19 pandemic on theAnti-Senescence Therapy division. The coronavirus epidemic is having an enormous impact on the global economic landscape and thus on this special line of business. Therefore, the report offers the reader a clear concept of the current scenario of this line of business and estimates the aftermath of COVID-19.

You can buy the complete report@ https://www.mraccuracyreports.com/checkout/205864

There are 15 Chapters to display the Global Anti-Senescence Therapy market

Chapter 1, Definition, Specifications and Classification of Anti-Senescence Therapy, Applications of Anti-Senescence Therapy, Market Segment by Regions;Chapter 2, Manufacturing Cost Structure, Raw Material and Suppliers, Manufacturing Process, Industry Chain Structure;Chapter 3, Technical Data and Manufacturing Plants Analysis of Anti-Senescence Therapy, Capacity and Commercial Production Date, Manufacturing Plants Distribution, R&D Status and Technology Source, Raw Materials Sources Analysis;Chapter 4, Overall Market Analysis, Capacity Analysis (Company Segment), Sales Analysis (Company Segment), Sales Price Analysis (Company Segment);Chapter 5 and 6, Regional Market Analysis that includes United States, China, Europe, Japan, Korea & Taiwan, Anti-Senescence Therapy Segment Market Analysis (by Type);Chapter 7 and 8, The Anti-Senescence Therapy Segment Market Analysis (by Application) Major Manufacturers Analysis of Anti-Senescence Therapy ;Chapter 9, Market Trend Analysis, Regional Market Trend, Market Trend by Product Type Gene Therapy, Immunotherapy, Others, Market Trend by Application Unity Biotechnology, OisinBiotechnologies, AgeX Therapeutics, Siwa Therapeutics, Cleara Biotech, Calico, Sierra Sciences, Human Longevity (HLI), Numeric Biotech, Recursion Pharmaceuticals, Proteostasis Therapeutics, Senolytic Therapeutics, Allergan , Others;Chapter 10, Regional Marketing Type Analysis, International Trade Type Analysis, Supply Chain Analysis;Chapter 11, The Consumers Analysis of Global Anti-Senescence Therapy ;Chapter 12, Anti-Senescence Therapy Research Findings and Conclusion, Appendix, methodology and data source;Chapter 13, 14 and 15, Anti-Senescence Therapy sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source.

GetExclusive Discount on this report @https://www.mraccuracyreports.com/check-discount/205864

About us:

MR Accuracy Reportsprovides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Contact Us:

Email:[emailprotected]

Website:www.mraccuracyreports.com

See the original post here:
Anti-Senescence Therapy Market Report Research Reports, Industry Size, In-Depth Qualitative Insights, Explosive Growth Opportunity, Regional Analysis...

LEEDS, England--(BUSINESS WIRE)-- 4D Pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs) - a novel class of drug derived from the microbiome, today announces the appointment of John Beck as Chief Financial Officer (CFO) and member of the Companys management team, bringing over 30 years of experience in finance, including three previous positions as Chief Financial Officer of publicly traded life sciences companies.

John will be an important addition to 4D pharmas management team at such a pivotal time, as the company prepares to close our SPAC merger and begin trading on NASDAQ. His deep experience and financial expertise as a CFO of several publicly traded life sciences companies will be critical as we further grow our company and global footprint, said Duncan Peyton, Chief Executive Officer of 4D pharma.

John Beck brings over 30 years of experience in financial and biopharmaceutical industry management experience. This includes three previous positions as Chief Financial Officer of publicly traded life sciences companies where he has achieved considerable results in areas including finance, business and corporate development, strategy, and commercialization.

I look forward to contributing the success of 4D pharma at this exciting stage in its development. 4Ds pioneering work to develop promising therapies across a number of disease areas from oncology to the gut-brain axis is clearly differentiated through its MicroRx platform and LBP product candidates, said John Beck, Chief Financial Officer of 4D pharma. With several key data readouts upcoming and our potential listing on NASDAQ, I believe 4D is well positioned to expand and enhance its investor base and drive further shareholder value for the remainder of 2021.

Mr. Beck has extensive investor and public relations, corporate governance, regulatory, and fundraising expertise. Most recently he was the Senior Vice President, Finance and CFO of Ritter Pharmaceuticals from May 2018 to May 2020, where he oversaw its successful merger with Qualigen Therapeutics, Inc. Prior to that, Mr. Beck served as Executive Manager and CEO at Wellspring Water Technologies, LLC and CEO of West Tech Medical, LLC from October 2015 to May 2018. Mr. Beck also was the CFO and Senior Vice President of Finance and Operations of Ardea Biosciences from February 2008 to June 2012, where he raised over $160 million in public financings, executed a $400 million out-licensing transaction with Bayer Pharmaceuticals and completed a $1.2 billion merger with AstraZeneca. Mr. Beck also held positions as Senior Vice President of Finance, Treasurer and CFO of Metabasis Therapeutics, and the Director of Finance at Neurocrine Biosciences, leading both through successful NASDAQ IPOs.

In addition, Mr. Beck currently serves on the Board of Directors of San Diego-based Artelo Biosciences, as a scientific advisor and mentor to the University of San Diegos student-run TRITON fund. Mr. Beck holds a B.A. in Accounting from the University of Washington, Seattle, a degree in theology from a Seattle area seminary and is a licensed CPA (inactive status) in the state of California.

About 4D pharma

Founded in February 2014, 4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D has developed a proprietary platform, MicroRx, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D pharma's Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma (NCT03851250), a Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19 (NCT04363372), and Blautix in Irritable Bowel Syndrome (IBS) (NCT03721107) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

In October 2020 4D pharma announced its intention to merge with Longevity Acquisition Corporation (NASDAQ: LOAC), a special purpose acquisition company (SPAC), and seek a NASDAQ listing. The merger is expected to be completed and the NASDAQ listing of 4D pharma American Depositary Shares (ADSs) under the ticker symbol 'LBPS' is currently expected to become effective in early 2021, subject to the satisfaction of closing conditions, including approval of 4D shareholders and Longevity shareholders and the approval by Nasdaq of the listing of ADSs.

For more information, refer to http://www.4dpharmaplc.com.

Forward-Looking Statements

This press release contains "forward-looking statements." All statements other than statements of historical fact contained in this announcement, including without limitation statements regarding timing of the clinical trial are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the United States Securities Exchange Act of 1934, as amended (the "Exchange Act"). Forward-looking statements are often identified by the words "believe," "expect," "anticipate," "plan," "intend," "foresee," "should," "would," "could," "may," "estimate," "outlook" and similar expressions, including the negative thereof. The absence of these words, however, does not mean that the statements are not forward-looking. These forward-looking statements are based on the Company's current expectations, beliefs and assumptions concerning future developments and business conditions and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates.

All of the Company's forward-looking statements involve known and unknown risks and uncertainties, some of which are significant or beyond its control, and assumptions that could cause actual results to differ materially from the Company's historical experience and its present expectations or projections. The foregoing factors and the other risks and uncertainties that affect the Company's business, including the risks of delays in the commencement of the clinical trial and those additional risks and uncertainties described the documents filed by the Company with the US Securities and Exchange Commission (SEC), should be carefully considered. The Company wishes to caution you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any of its forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except to the extent required by law.

Additional Information about the Transaction and Where to Find it

This press release is being made in respect of a proposed business combination involving 4D and Longevity. Following the announcement of the proposed business combination, 4D filed a registration statement on Form F-4 (the Registration Statement) with the SEC which was declared effective on February 25, 2021. This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities or a solicitation of any vote or approval nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Registration Statement includes a prospectus with respect to 4Ds ordinary shares and ADSs to be issued in the proposed transaction and a proxy statement of Longevity in connection with the merger. The proxy statement/prospectus has been mailed to the Longevity shareholders on or about February 26, 2021. 4D and Longevity also plan to file other documents with the SEC regarding the proposed transaction.

This press release is not a substitute for any prospectus, proxy statement or any other document that 4D or Longevity may file with the SEC in connection with the proposed transaction. Investors and security holders are urged to read the Registration Statement and, when they become available, any other relevant documents that will be filed with the SEC carefully and in their entirety because they will contain important information about the proposed transaction.

You may obtain copies of all documents filed with the SEC regarding this transaction, free of charge, at the SECs website (www.sec.gov). In addition, investors and security holders will be able to obtain free copies of the Registration Statement and other documents filed with the SEC without charge, at the SECs website (www.sec.gov) or by calling +1-800-SEC-0330.

Participants in the Solicitation

Longevity and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from Longevitys shareholders with respect to the proposed transaction. Information regarding Longevitys directors and executive officers is available in its annual report on Form 10-K for the fiscal year ended February 29, 2020, filed with the SEC on April 30, 2020. Additional information regarding the participants in the proxy solicitation relating to the proposed transaction and a description of their direct and indirect interests is contained in the Registration Statement.

4D and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Longevity in connection with the proposed transaction. A list of the names of such directors and executive officers and information regarding their interests in the proposed transaction is included in the Registration Statement.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210301005053/en/

Original post:
4D Pharma Appoints John Beck as Chief Financial Officer and Member of the Management Team - BioSpace

Its time to stop mythologizing Black women trying to survive in a world that doesnt value them.

Content warning: police violence, Black death

Black women arent your superheroes. We arent selfless vigilantes, watching through the night for signs of trouble. Were not perched on the wings of the city, waiting to swoop in and save white people in distress.

Black women are human amazing, creative, self-sacrificing humans but human nonetheless. We save others to save ourselves.

But continual demands on Black women to act while others do nothing is killing us.

The last 12 months of nonstop political and cultural turmoil a pandemic, constant images of police brutality, contested elections, insurrection have only further proven how invaluable Black women are to society.

These recent affairs have produced countless examples of Black women turned into superhero caricatures by the white gaze; white people are obsessed with us, obsessed with what we can do for them.

Amanda Gorman, the Youth Poet Laureate who spoke at President Bidens inauguration, has been portrayed as a larger-than-life superhero, a magical being meant to save the United States from itself.

Stacey Abrams (with a coalition of other Black women) helped expand voter accessibility in Georgia. Shes being painted as an almost fanciful champion, saving marginalized votes from the evil clutches of voter suppression tactics without so much as breaking a sweat.

Black women, as a collective, helped the Democratic Party crawl to victory in the 2020 presidential election.

Dont get it twisted; these Black women are wholeheartedly brilliant full stop but white people have mythologized them.

Black women have gone from attentive citizens participating in democracy to protect their communities interests to Americas safety net. Shine the Bat-Signal and well be there in 5.

Beyond establishment politics, Black women are also at the front lines of revolutionary work, slaying systems that disproportionately execute Black people.

Black women have led the months of protests, calling for reverence toward Black life (long after supposed white allies fell to the wayside).

Were the ones creating and circulating calls to action. Were the ones making posters for protests. Were the ones giving our time and energy to various marches and rallies.

Black women do the bulk of organizing, leading, and participating in these revolutionary moments as others stand aside and contribute little beyond pledges to do better.

We save democracies. We save our people. All while juggling personal responsibilities and bearing the cross of what it means to be a Black woman in the world.

And yet, despite the deep and abundant ways that Black women serve everyone, no one shows up for us. No one thanks us for the labor we do at least not in any meaningful way.

No one cares about our constant exhaustion given the trauma and pain we carry and what it does to us physically, emotionally, and mentally.

When it comes to opportunities to show up for us and with us, people rarely find the time. Theyre lackluster about showing any solidarity or support for us; the dedication isnt reciprocated.

Historically, movements like first-wave feminism pushed out Black women in fear that our calls for humanity would weaken the overall movement. Even as Black trans women led the queer liberation movement of the 1960s and 70s, their critical involvement is routinely forgotten.

Currently, rallies for #SayHerName have notably fewer attendants. In fact, the hashtag we created to highlight our unique plight has been co-opted and misused, silencing our message.

Vigils honoring Black trans women are quietly circulated and sparsely attended.

Instead of celebrating the work Black women do and the investments we constantly make in others, the world harms us. The world hates us. The world finds new and innovative ways to humiliate, degrade, and commit violence upon us.

People especially white people who self-consciously tweet about thanking Black women use Black women as a steppingstone to continue living a life of ignorant bliss and placidity.

Despite our cultural and political climate demanding that people finally respect the fullness and beauty of Black life, people still find it in their chest to disrespect and dehumanize Black women.

The killings of Breonna Taylor, Nina Pop, and countless other Black women show how disposable we are.

The fact that the officer who killed Breonna Taylor was punished for wanton endangerment (for the bullets that hit a neighboring apartments walls) versus the bullets that sliced through Breonnas body shows how little Black women matter.

Charges were brought for endangering human life as if Breonnas life wasnt snatched without hesitation. Let this sentencing and others without a flake of justice show how Black women are regarded in this life.

Black women are the victims of all kinds of violence.

The violence looks like being categorically harassed on Twitter by all different races of men.

The violence looks like Talib Kweli dedicating hours upon hours of tweeting to harass Maya Moody, a Black woman whom he had a disagreement with.

The violence looks like Black women being disproportionately affected by and dying from domestic violence.

The violence looks like the epidemic of Black trans women being murdered.

The violence looks like Megan Thee Stallion being shot by Tory Lanez and having her fellow music industry colleagues stay silent about her abuse. It looks like people mocking her trauma, calling her a snitch, and making jokes at her expense.

These types of hate and vitriol are specifically reserved for us.

Our physical and mental health is impaired as people stand around and watch us suffer.

Black women are disproportionately affected by mental health conditions like anxiety, having more intense and chronic symptoms compared with our white counterparts.

Our physical pain is routinely downplayed and undertreated by white doctors.

Black women also have a higher risk of developing and dying from illnesses such as heart disease and cancer.

Were often told these health disparities stem from lifestyle factors, despite research that says otherwise.

Our bodies are literally being worn down by the stress we face, further proving that the lived reality of Black women isnt just a trendy political discussion point. Its an all too real public health crisis that erodes at our very being.

The way that the United States continually burdens Black women with its demands for our intelligence, our sympathy, our action, and our myriad other talents, all the while ignoring our well-being and humanity, is a problem.

Its an issue thats literally killing us. As Black women, we have a responsibility to ourselves to practice self-care and preservation. Of course, the practical ability to do this is difficult considering every crisis that plagues anyone will befall us 10 times worse.

Whenever possible, though, we need to draw boundaries and put ourselves first.

And the wave of people who shower us with empty thanks on social media while doing nothing material to protect our welfare also have a responsibility. Simply put: You all need to legitimately and unquestionably ride for us.

You need to give your money to Black women who are on the front lines. You need to give your money to Black women who move through the world, simply trying to survive.

You need to use your platform to decry the injustices Black women suffer, who die at the hands of misogynoir.

You need to listen to Black women, when we tell you we are hurting, when we tell you that you are hurting us.

You need to examine and unlearn your assumptions about what Black women do and do not owe you (spoiler alert: we owe you nothing).

You need to stop treating us like your emergency brake, as if were only placed on this earth to serve.

Black women deserve to experience the fullness of life without being run ragged by the demands of others.

We should be able to live with some dignity without fearing violence or a premature death because of what the world does to us.

Everyone absolutely everyone has a part to play in ensuring that Black women are protected and showing us that we matter.

Gloria Oladipo is a Black woman and freelance writer, musing about all things race, mental health, gender, art, and other topics. You can read more of her funny thoughts and serious opinions on Twitter.

More here:
As Black Women, We Need to Save Ourselves, Not the World - Healthline

The Action Plan of the European Pillar of Social Rights could lead to a profound shift in the enjoyment of human rights in the EU.

The pandemic and the measures taken to combat it have upended many lives. For millions around the world, Covid-19 has brought protracted uncertainty, isolation and hardship, with no end in sight.

The global poverty rate is likely to increase for the first time in 20 years, risking the reversal of substantial gains. The United Nations secretary-general, Antnio Guterres, has called for a global reset as the world continues to reel from the pandemic, which has claimed more than two million lives and some 500 million jobs.

In Europe, the detrimental impact on the right to physical and mental health has been compounded by over-reliance on the institutional care of older persons and persons with disabilities. And those already in a precarious situation have been hit hardest, with women and minorities particularly afflicted.

At the beginning of last week, the Council of the EU adopted conclusions on a human-rights-based post-Covid-19 recovery, restating the indivisibility of all human rights and reaffirming that a socio-economic response with human rights at its core would enable a more sustainable recovery and make systems more resilient to future shocks. A week earlier, in a joint communication on multilateralism from the European Commission and the high representative for foreign affairs and security policy, the EUs commitment to human rights was presented not only as a matter of values but as an essential component of its support for a rules-based international order.

But the commitment must start at homewith a human-rights-based approach to the Action Plan, due tomorrow, to implement the European Pillar of Social Rights agreed in 2017.

"Social Europe publishes thought-provoking articles on the big political and economic issues of our time analysed from a European viewpoint. Indispensable reading!"

Columnist for The Guardian

Thank you very much for your interest! Now please check your email to confirm your subscription.

Expectations are high for the Action Planfor improving working conditions, tackling homelessness and enhancing social protection. Rightly so, because the pandemic has created an unprecedented opportunity for the EU to trigger a seismic shift in the enjoyment of social rights in the union.

An approach that places human beings and their rights at its centrenot as passive recipients of services but as rights-holders with agencyis the only route to a sustainable recovery. The plan should be guided by international human-rights treaties and recommendations, as well as the UNs 2030 Agenda for Sustainable Development.

While states, as primary duty-bearers under international law, carry the main responsibility to respect, protect and fulfil social rights, the role of the EU institutions cannot be overstated. A rights-based approach will not only help close protection gaps for people living in Europe; it will also strengthen coherence among international, regional and national systems and enhance legal certainty for member states and domestic courts.

But this is about more than compliance: international human rights can sharpen the effectiveness of policy interventions. In addition to the EUs own tools, such as the Social Scoreboard, the findings of UN treaty bodies establish a useful baseline as to where countries stand in terms of social rights. As parties to the UN Convention on Economic, Social and Cultural Rights, member states are, after all, bound to implement these norms. In this vein, the Action Plan should also explicitly recognise adequate housing and social protection as matters of human rightsnot as a commodity or as services.

As you may know, Social Europe is an independent publisher. We aren't backed by a large publishing house or big advertising partners. For the longevity of Social Europe we depend on our loyal readers - we depend on you. You can support us by becoming a Social Europe member for less than 5 Euro per month.

Thank you very much for your support!

It is precisely at this time of crisis that solid public participation is needed. Rights-holders should be enabled to participate effectively in the implementation and review of the social pillarespecially representatives of the most marginalised. To collect reliable information on who they are, the Action Plan should call on states to collect data on socio-economic status, disaggregated by age, sex, race/ethnicity, national origin, disability, education and property.

Because of their proximity to the citizen, local and regional authorities should be more involved in formulating policy. Their views on what works and what doesnt, in healthcare, housing or employment, including job creation, are critical to designing and implementing policies that work for all.

Clear quantitative and qualitative targets should be set and accompanied by a robust system to measure results. Indicators already exist to track and assess progresson human rights from the UN Human Rights Office plus those associated with the Sustainable Development Goals. The Action Plan should also envisage transparent and publicly accessible tools to track linked financial allocations and expenditures.

The EU and its member states have been the strongest supporters of national human-rights institutions around the world and should systematically bring them on board in the Action Plan. National human-rights institutions are state-mandated bodies, independent of government, which advise on legislation, monitor human-rights compliance, raise public awareness and help individuals claim their rights. They also act as a bridge to the international human-rights system.

By aligning its internal policies with its vision for external action, as also articulated in the EU Action Plan for Human Rights and Democracy, Europe can lead by example. But internal coherence will also be central to the plans success. Hence, the importance of joined-up implementation with various other EU policies seeking to advance economic and social rights: the Disability Strategy, the Anti-Racism Action Plan, the Gender Equality Strategy, the Child Guarantee, the Youth Guarantee, the Strategic Framework on Roma Equality and Inclusion, and the LGBTI+ Equality Strategy.

We have before us a chance to close serious gaps in the enjoyment of social rights across the region. If this opportunity is seized, it will lead to better and tangible outcomes in the Covid-19 recovery andmost importantlywill guarantee a life of greater dignity for all.

Go here to see the original:
Aligning the social pillar with human rights - Social Europe